NEW YORK (GenomeWeb News) - Entelos said today that has signed an agreement with Johnson & Johnson Pharmaceutical Research & Development to use its predictive computer models of human physiology to study new therapies for type-2 diabetes.
 
Under the agreement, Entelos will use its in silico “virtual patients” to discover and evaluate therapies for the disease.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.